Dr. Wayne Macfadden | Central Nervous System Clinical Science Leader at Roche
About Wayne MacfaddenA Clinical Science Leader of the Central Nervous System team at Roche, Dr. Wayne Macfadden has authored or co-authored nearly two dozen articles for professional journals and books. Most of Dr. Macfadden's recent publications have addressed drug therapies and clinical trials for the treatment of bipolar disorder and schizophrenia. Dr. Wayne Macfadden was first author on the article "Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results," in a 2011 issue of BMC Psychiatry. Dr. Macfadden also contributed to other research papers published in peer-reviewed journals, including the American Journal of Psychiatry.Earlier in his career, Dr. Wayne Macfadden co-authored a study of a double-blind trial of Quetiapine versus a placebo as a treatment for Type A and Type B alcoholism, published in the Journal of Clinical Psychopharmacology. Dr. Macfadden also designed clinical trials of Quetiapine for treatment of acute bipolar depression. A series of articles on these trials appeared in the Journal of Clinical Psychiatry, Bipolar Disorders, and International Clinical Psychopharmacology. In the 1990s, Dr. Wayne Macfadden contributed to the 1994 edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and authored a chapter on Cannabis for the sixth edition of the Comprehensive Textbook of Psychiatry. Dr. Wayne Macfadden has a Bachelor of Science in Biomedical Science from the City College of New York . He completed his M.D. at the State University of New York at Buffalo School of Medicine and accepted an internship in internal medicine at Millard Fillmore Hospital in Buffalo. Dr. Macfadden performed his residency in psychiatry at the University of Pennsylvania's Perelman School of Medicine. |
